Results 191 to 200 of about 5,008,337 (326)

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

38-Marker Full-Spectrum Flow Cytometry Panel for the Comprehensive Profiling of γδ T Cells in Human Blood and Lymphoid Tissues. [PDF]

Eur J Immunol
Hamed M, Moreno-Vicencio D, Arsovski D, Farhat M, Sanders R, Mann E, Bennett A, Chevour P, Davey MS.   +8 more
europepmc   +1 more source

Proteome profiling outperforms transcriptome profiling for coexpression based gene function prediction [PDF]

, 2017
et al.,, Townsend, R. Reid
core   +1 more source

GenomeScope: Fast reference-free genome profiling from short reads

bioRxiv, 2016
Gregory W. Vurture, F. Sedlazeck, Maria Nattestad, C. Underwood, Han Fang, James Gurtowski, M. Schatz   +6 more
semanticscholar   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Comparative analysis of alkyne- and desthiobiotinylated photoaffinity probes for chemotranscriptomic profiling. [PDF]

RSC Chem Biol
van den Homberg DAL, Poulladofonou G, Dekens A, Velema WA.   +3 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Clinical potential and challenges of spatially profiling tumor-infiltrating lymphocytes in early-stage breast cancer. [PDF]

PLoS Med
Page DB, Simanonok M, Hanes DA, Su A.
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Erratum: Expanded methylome and quantitative trait loci detection by long-read profiling of personal DNA. [PDF]

Genome Res
Groza C, Ge B, Cheung WA, Pastinen T, Bourque G.   +4 more
europepmc   +1 more source